Iluvien has been approved by Health Canada, Alimera Sciences announced in a press release.
A fluocinolone acetonide sustained-release intravitreal implant, Iluvien is already approved in the U.S. to treat diabetic macular edema.
“We are excited that Iluvien has received approval by Health Canada,” Alimera CEO Dan Myers said in the release. “Iluvien is the only treatment approved in Canada with continuous microdosing that can treat DME every day for up to 3 years with a single implant.”
The company has an exclusive Canadian agreement with Knight Therapeutics, which will begin working with public and private payers to seek reimbursement for Iluvien.